Literature DB >> 22621932

Transforming growth factor β1 (TGF-β1) suppresses growth of B-cell lymphoma cells by p14(ARF)-dependent regulation of mutant p53.

Gang Chen1, Paritosh Ghosh, Thomas O'Farrell, Rachel Munk, Louis J Rezanka, Carl Y Sasaki, Dan L Longo.   

Abstract

Previously we reported that TGF-β1-induced growth suppression was associated with a decrease in mutant p53 levels in B-cell lymphoma cells. The goal of the present study was to understand the mechanism involved in TGF-β1-mediated down-regulation of mutant p53. In RL and CA46, two B-cell lymphoma cell lines, TGF-β1 treatment caused down-regulation of E2F-1 transcription factor resulting in the down-regulation of both p14(ARF) and mutant p53, leading to growth arrest. Experimental overexpression of E2F-1 increased p14(ARF) level and blocked TGF-β1-induced down-regulation of p14(ARF). Overexpression of p14(ARF) blocked the down-regulation of mutant p53 and prevented growth arrest. p14(ARF) also attenuated TGF-β1-induced p21(Cip1/WAF1) induction, which was reversible by p53 siRNA, indicating the involvement of mutant p53 in controlling the TGF-β1-induced expression of p21(Cip1/WAF1). The interaction observed between phospho-Smad2 and mutant p53 in the nucleus could be the mechanism responsible for blocking the growth-suppressive effects of TGF-β1. In RL cells, p14(ARF) is present in a trimer consisting of mutant p53-Mdm2-p14(ARF) and in a dimer consisting of Mdm2-p14(ARF). Because it is known that Mdm2 can degrade p53, it is possible that, in its trimeric form, p14(ARF) is able to stabilize mutant p53 by inhibiting Mdm2. In its dimeric form, p14(ARF) may be sequestering Mdm2, limiting its ability to degrade p53. Collectively, these data demonstrate a unique mechanism in which the inhibition of TGF-β1-mediated growth suppression by mutant p53 can be reversed by the down-regulation of its stabilizing protein p14(ARF). This work suggests that the high levels of p14(ARF) often found in tumor cells could be a potential therapeutic target.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22621932      PMCID: PMC3391099          DOI: 10.1074/jbc.M112.351411

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

Review 1.  Gain of function properties of mutant p53 proteins at the mitotic spindle cell cycle checkpoint.

Authors:  M L Hixon; A Flores; M Wagner; A Gualberto
Journal:  Histol Histopathol       Date:  2000-04       Impact factor: 2.303

2.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

3.  High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors.

Authors:  P Salmon; V Kindler; O Ducrey; B Chapuis; R H Zubler; D Trono
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

Review 4.  Assessing TP53 status in human tumours to evaluate clinical outcome.

Authors:  T Soussi; C Béroud
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

5.  Inhibition of v-Abl transformation by p53 and p19ARF.

Authors:  F Cong; X Zou; K Hinrichs; K Calame; S P Goff
Journal:  Oncogene       Date:  1999-12-16       Impact factor: 9.867

6.  ARF function does not require p53 stabilization or Mdm2 relocalization.

Authors:  Chandrashekhar Korgaonkar; Lili Zhao; Modestos Modestou; Dawn E Quelle
Journal:  Mol Cell Biol       Date:  2002-01       Impact factor: 4.272

7.  Human tumor suppressor ARF impedes S-phase progression independent of p53.

Authors:  Wendell G Yarbrough; Mika Bessho; Adam Zanation; John E Bisi; Yue Xiong
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

Review 8.  Decision making by p53: life, death and cancer.

Authors:  M Oren
Journal:  Cell Death Differ       Date:  2003-04       Impact factor: 15.828

9.  p14(ARF) nuclear overexpression in aggressive B-cell lymphomas is a sensor of malfunction of the common tumor suppressor pathways.

Authors:  Abel Sánchez-Aguilera; Margarita Sánchez-Beato; Juan F García; Ignacio Prieto; Marina Pollan; Miguel A Piris
Journal:  Blood       Date:  2002-02-15       Impact factor: 22.113

Review 10.  Tumor suppression by Ink4a-Arf: progress and puzzles.

Authors:  Scott W Lowe; Charles J Sherr
Journal:  Curr Opin Genet Dev       Date:  2003-02       Impact factor: 5.578

View more
  7 in total

1.  A single nucleotide polymorphism in the TGF-β1 gene (rs1982073 C>T) may contribute to increased risks of bone fracture, osteoporosis, and osteoarthritis: a meta-analysis.

Authors:  Yu Cong; Jiang-Ying Ru; Ni-Rong Bao; Ting Guo; Jian-Ning Zhao
Journal:  Clin Rheumatol       Date:  2014-12-13       Impact factor: 2.980

2.  Histone demethylase RBP2 promotes malignant progression of gastric cancer through TGF-β1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit.

Authors:  Xiuming Liang; Jiping Zeng; Lixiang Wang; Li Shen; Xueping Ma; Shuyan Li; Yujiao Wu; Lin Ma; Xinyu Ci; Qing Guo; Mutian Jia; Haiyu Shen; Yundong Sun; Zhifang Liu; Shili Liu; Wenjuan Li; Han Yu; Chunyan Chen; Jihui Jia
Journal:  Oncotarget       Date:  2015-07-10

3.  TGF-β3 Inhibits Antibody Production by Human B Cells.

Authors:  Yumi Tsuchida; Shuji Sumitomo; Kazuyoshi Ishigaki; Akari Suzuki; Yuta Kochi; Haruka Tsuchiya; Mineto Ota; Toshihiko Komai; Mariko Inoue; Kaoru Morita; Tomohisa Okamura; Kazuhiko Yamamoto; Keishi Fujio
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

4.  Grainyhead-like 2 (GRHL2) knockout abolishes oral cancer development through reciprocal regulation of the MAP kinase and TGF-β signaling pathways.

Authors:  Wei Chen; Kyung L Kang; Abdullah Alshaikh; Saaket Varma; Yi-Ling Lin; Ki-Hyuk Shin; Reuben Kim; Cun-Yu Wang; No-Hee Park; Katharina Walentin; Kai M Schmidt-Ott; Mo K Kang
Journal:  Oncogenesis       Date:  2018-05-08       Impact factor: 7.485

5.  AKT regulates NPM dependent ARF localization and p53mut stability in tumors.

Authors:  Garth Hamilton; Aswin G Abraham; Jennifer Morton; Oliver Sampson; Dafni E Pefani; Svetlana Khoronenkova; Anna Grawenda; Angelos Papaspyropoulos; Nigel Jamieson; Colin McKay; Owen Sansom; Grigory L Dianov; Eric O'Neill
Journal:  Oncotarget       Date:  2014-08-15

Review 6.  Post-Translational Regulation of ARF: Perspective in Cancer.

Authors:  Jinho Seo; Daehyeon Seong; Seung Ri Lee; Doo-Byoung Oh; Jaewhan Song
Journal:  Biomolecules       Date:  2020-08-04

7.  Curcumin in combination with homoharringtonine suppresses lymphoma cell growth by inhibiting the TGF-β/Smad3 signaling pathway.

Authors:  Yu Zhang; Jingjing Xiang; Ni Zhu; Hangping Ge; Xianfu Sheng; Shu Deng; Junfa Chen; Lihong Yu; Yan Zhou; Jianping Shen
Journal:  Aging (Albany NY)       Date:  2021-07-29       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.